biomarkers
PR Newswire: iLoF and Industry Leader Hamamatsu Announce Strategic Investment in a Collaboration to Advance the Future of Personalized Medicine
iLoF, the leading innovator in AI-powered photonics platforms for personalised medicine, announces today a strategic investment from Hamamatsu, the world expert in the development and manufacturing of photonics devices and systems for medical optics and biophotonics, to further its mission of transforming healthcare and driving innovation in medicine. LONDON, Oct. 22, 2024 /PRNewswire/ — iLoF, the leading company […]
Read more »
Alzheimer’s Data Challenge Names Winners for Innovative Biomarker Research Competition
Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data Competition Washington D.C., Mar. 27, 2025 – International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) and the Alzheimer’s Disease Data Initiative proudly announced four winners of the Bio-Hermes Biomarker Data Challenge at the first Data […]
Read more »
The Pathologist: No Alzheimer’s Patient Left Behind
A blood-based diagnostic test for neurodegenerative diseases is a global priority By Zivjena Vucetic 03/21/2025 As the global population ages, the incidence of neurodegenerative diseases such as Alzheimer’s disease (AD) is rapidly increasing. By 2050, the global population of people over the age of 60 is expected to double, reaching 2.1 billion individuals, while those over 80 […]
Read more »Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Roche for the Transformative Bio-Hermes-002 Study
Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]
Read more »Beckman Coulter Diagnostics Joins the Transformative Bio-Hermes-002 Study as New Partner
Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]
Read more »